[SCHEDULE 13G/A] Grace Therapeutics, Inc. SEC Filing
Grace Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its principals Wilmot B. Harkey and Daniel Mack together may be deemed beneficial owners of 1,404,032 shares of Grace Therapeutics common stock, representing 9.99% of the class as of June 30, 2025. The reported position is held by funds and separately managed accounts under Nantahala's control and includes 225,831 shares that may be acquired within sixty days through the exercise of warrants. The filing shows no sole voting or dispositive power; all voting and dispositive authority is reported as shared among the reporting persons.
Grace Therapeutics, Inc. Nel modulo Schedule 13G/A si segnala che Nantahala Capital Management, LLC e i suoi soci Wilmot B. Harkey e Daniel Mack possono essere considerati comproprietari di 1.404.032 azioni ordinarie di Grace Therapeutics, pari al 9,99% della categoria alla data del 30 giugno 2025. La posizione comunicata 猫 detenuta da fondi e conti gestiti separatamente sotto il controllo di Nantahala e include 225.831 azioni che potrebbero essere acquisite entro sessanta giorni attraverso l鈥檈sercizio di warrant. La dichiarazione indica assenza di poteri di voto o dispositivi in via esclusiva; tutti i poteri di voto e dispositivi sono riportati come condivisi tra le persone che presentano la comunicazione.
Grace Therapeutics, Inc. El informe Schedule 13G/A comunica que Nantahala Capital Management, LLC y sus responsables Wilmot B. Harkey y Daniel Mack pueden ser considerados propietarios beneficiarios de 1.404.032 acciones ordinarias de Grace Therapeutics, lo que representa el 9,99% de la clase a fecha del 30 de junio de 2025. La posici贸n informada est谩 en fondos y cuentas gestionadas por separado bajo el control de Nantahala e incluye 225.831 acciones que podr铆an adquirirse dentro de sesenta d铆as mediante el ejercicio de warrants. La presentaci贸n muestra ning煤n poder exclusivo de voto o disposici贸n; toda la autoridad de voto y dispositiva se declara compartida entre las personas que informan.
Grace Therapeutics, Inc. Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� Nantahala Capital Management, LLC鞕� 攴� 鞛勳洂 Wilmot B. Harkey 氚� Daniel Mack鞚� 2025雲� 6鞗� 30鞚� 旮办 Grace Therapeutics 氤错喌欤� 1,404,032欤茧ゼ 鞁れ 氤挫湢鞛愲 臧勳＜霅� 靾� 鞛堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 9.99%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 Nantahala鞚� 甏�毽� 頃橃棎 鞛堧姅 韼�霌� 氚� 氤勲弰 鞖挫毄 瓿勳臧� 氤挫湢頃橁碃 鞛堨溂氅�, 60鞚� 鞚措偞鞐� 鞗岆煱韸� 頄夓偓搿� 旆摑頃� 靾� 鞛堧姅 225,831欤�毳� 韽暔頃╇媹雼�. 鞝滌稖靹滊電� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇澊 鞐嗢潓鞚� 雮橅儉雮措┌; 氇摖 鞚橁舶甓� 氚� 觳橂秳甓岇潃 氤搓碃鞛愲摛 臧勳棎 瓿奠湢霅橂姅 瓴冹溂搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
Grace Therapeutics, Inc. Le Schedule 13G/A indique que Nantahala Capital Management, LLC et ses dirigeants Wilmot B. Harkey et Daniel Mack peuvent 锚tre consid茅r茅s comme d茅tenteurs effectifs de 1 404 032 actions ordinaires de Grace Therapeutics, repr茅sentant 9,99 % de la cat茅gorie au 30 juin 2025. La position d茅clar茅e est d茅tenue par des fonds et des comptes g茅r茅s s茅par茅ment sous le contr么le de Nantahala et inclut 225 831 actions pouvant 锚tre acquises dans les soixante jours par l鈥檈xercice de bons de souscription (warrants). Le d茅p么t fait 茅tat de aucun pouvoir de vote ou de disposition exclusif ; tous les pouvoirs de vote et de disposition sont d茅clar茅s partag茅s entre les personnes d茅posantes.
Grace Therapeutics, Inc. Aus dem Schedule 13G/A geht hervor, dass Nantahala Capital Management, LLC und deren Verantwortliche Wilmot B. Harkey und Daniel Mack gemeinsam als wirtschaftliche Eigent眉mer von 1.404.032 Aktien der Grace Therapeutics Stammaktien angesehen werden k枚nnen, was zum 30. Juni 2025 9,99% der Klasse entspricht. Die gemeldete Position wird von Fonds und separat verwalteten Konten unter der Kontrolle von Nantahala gehalten und umfasst 225.831 Aktien, die innerhalb von sechzig Tagen durch Aus眉bung von Warrants erworben werden k枚nnten. Die Einreichung weist keine alleinige Stimm- oder Verf眉gungsbefugnis aus; alle Stimm- und Verf眉gungsbefugnisse werden als zwischen den meldenden Personen geteilt gemeldet.
- Transparent disclosure of beneficial ownership at 9.99% for Nantahala and the named individuals
- Includes exercisable warrants in the beneficial ownership total (225,831 shares), clarifying near-term potential interest
- No sole voting or dispositive power reported; all authority is listed as shared rather than sole
- Position is just below 10%, which may limit certain disclosure classifications (reported as Schedule 13G/A rather than a 13D)
Insights
TL;DR: Nantahala reports a just-under-10% stake (including exercisable warrants) with shared voting and dispositive power, disclosed under Schedule 13G/A.
The filing indicates passive ownership held in the ordinary course by an investment adviser and its principals. The 9.99% figure is material for disclosure thresholds and includes 225,831 shares exercisable within sixty days, which is relevant to calculating potential voting dilution. Absence of sole voting or dispositive power suggests control is not asserted by the reporting persons; the filing is consistent with a passive investor disclosure rather than an active control filing.
TL;DR: Reporting structure shows shared authority and classification as an investment adviser filing, implying compliance with passive investor rules.
The statement classifies Nantahala as an investment adviser and Messrs. Harkey and Mack as control persons only to the extent of their roles with Nantahala. The explicit inclusion of warrants exercisable within sixty days is appropriate for beneficial ownership calculation. The filing does not indicate group formation or any intention to influence issuer control, and it provides clear allocation of voting and dispositive powers as shared rather than sole.
Grace Therapeutics, Inc. Nel modulo Schedule 13G/A si segnala che Nantahala Capital Management, LLC e i suoi soci Wilmot B. Harkey e Daniel Mack possono essere considerati comproprietari di 1.404.032 azioni ordinarie di Grace Therapeutics, pari al 9,99% della categoria alla data del 30 giugno 2025. La posizione comunicata 猫 detenuta da fondi e conti gestiti separatamente sotto il controllo di Nantahala e include 225.831 azioni che potrebbero essere acquisite entro sessanta giorni attraverso l鈥檈sercizio di warrant. La dichiarazione indica assenza di poteri di voto o dispositivi in via esclusiva; tutti i poteri di voto e dispositivi sono riportati come condivisi tra le persone che presentano la comunicazione.
Grace Therapeutics, Inc. El informe Schedule 13G/A comunica que Nantahala Capital Management, LLC y sus responsables Wilmot B. Harkey y Daniel Mack pueden ser considerados propietarios beneficiarios de 1.404.032 acciones ordinarias de Grace Therapeutics, lo que representa el 9,99% de la clase a fecha del 30 de junio de 2025. La posici贸n informada est谩 en fondos y cuentas gestionadas por separado bajo el control de Nantahala e incluye 225.831 acciones que podr铆an adquirirse dentro de sesenta d铆as mediante el ejercicio de warrants. La presentaci贸n muestra ning煤n poder exclusivo de voto o disposici贸n; toda la autoridad de voto y dispositiva se declara compartida entre las personas que informan.
Grace Therapeutics, Inc. Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� Nantahala Capital Management, LLC鞕� 攴� 鞛勳洂 Wilmot B. Harkey 氚� Daniel Mack鞚� 2025雲� 6鞗� 30鞚� 旮办 Grace Therapeutics 氤错喌欤� 1,404,032欤茧ゼ 鞁れ 氤挫湢鞛愲 臧勳＜霅� 靾� 鞛堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 9.99%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 Nantahala鞚� 甏�毽� 頃橃棎 鞛堧姅 韼�霌� 氚� 氤勲弰 鞖挫毄 瓿勳臧� 氤挫湢頃橁碃 鞛堨溂氅�, 60鞚� 鞚措偞鞐� 鞗岆煱韸� 頄夓偓搿� 旆摑頃� 靾� 鞛堧姅 225,831欤�毳� 韽暔頃╇媹雼�. 鞝滌稖靹滊電� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇澊 鞐嗢潓鞚� 雮橅儉雮措┌; 氇摖 鞚橁舶甓� 氚� 觳橂秳甓岇潃 氤搓碃鞛愲摛 臧勳棎 瓿奠湢霅橂姅 瓴冹溂搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
Grace Therapeutics, Inc. Le Schedule 13G/A indique que Nantahala Capital Management, LLC et ses dirigeants Wilmot B. Harkey et Daniel Mack peuvent 锚tre consid茅r茅s comme d茅tenteurs effectifs de 1 404 032 actions ordinaires de Grace Therapeutics, repr茅sentant 9,99 % de la cat茅gorie au 30 juin 2025. La position d茅clar茅e est d茅tenue par des fonds et des comptes g茅r茅s s茅par茅ment sous le contr么le de Nantahala et inclut 225 831 actions pouvant 锚tre acquises dans les soixante jours par l鈥檈xercice de bons de souscription (warrants). Le d茅p么t fait 茅tat de aucun pouvoir de vote ou de disposition exclusif ; tous les pouvoirs de vote et de disposition sont d茅clar茅s partag茅s entre les personnes d茅posantes.
Grace Therapeutics, Inc. Aus dem Schedule 13G/A geht hervor, dass Nantahala Capital Management, LLC und deren Verantwortliche Wilmot B. Harkey und Daniel Mack gemeinsam als wirtschaftliche Eigent眉mer von 1.404.032 Aktien der Grace Therapeutics Stammaktien angesehen werden k枚nnen, was zum 30. Juni 2025 9,99% der Klasse entspricht. Die gemeldete Position wird von Fonds und separat verwalteten Konten unter der Kontrolle von Nantahala gehalten und umfasst 225.831 Aktien, die innerhalb von sechzig Tagen durch Aus眉bung von Warrants erworben werden k枚nnten. Die Einreichung weist keine alleinige Stimm- oder Verf眉gungsbefugnis aus; alle Stimm- und Verf眉gungsbefugnisse werden als zwischen den meldenden Personen geteilt gemeldet.
FAQ
How many shares of GRCE does Nantahala Capital Management report owning?
What percentage of GRCE does the 13G/A filing represent?
Does the filing include options or warrants in the ownership total for GRCE?
Do the reporting persons claim sole voting or dispositive power over GRCE shares?
Under what classification is Nantahala filing this statement?
